Analysts Set Expectations for Affimed FY2025 Earnings

Affimed (NASDAQ:AFMD) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Affimed in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings per share of ($2.07) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.10) per share.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus cut their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Price Performance

NASDAQ AFMD opened at $1.14 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The company has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $3.31. Affimed has a 52-week low of $1.03 and a 52-week high of $8.95.

Institutional Investors Weigh In On Affimed

A number of hedge funds have recently made changes to their positions in AFMD. Point72 Asset Management L.P. raised its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Jane Street Group LLC acquired a new position in Affimed during the 3rd quarter worth about $44,000. Intellectus Partners LLC grew its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the last quarter. Finally, FMR LLC grew its holdings in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.